peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Stock on mobile

Stock information

Stock quote HNSA – OMX Stockholm

Quotes are delayed 15 minutes. Information provided by Cision.

Stock Chart

SEK
Volume, thousands
[{"d":"2022-08-22","n":"Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-and-medison-pharma-announce-positive-reimbursement-decision-in-poland-for-idefirix-in-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-09-09","n":"Hansa Biopharma: Issue and repurchase of class C shares for incentive programs","u":"/media/press-releases/2022/hansa-biopharma-issue-and-repurchase-of-class-c-shares-for-incentive-programs/"},{"d":"2022-09-12","n":"The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/the-scottish-medicines-consortium-smc-recommends-use-of-hansa-biopharmas-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-09-30","n":"Hansa Biopharma achieves Great Place to Work[®] certification for the third consecutive year","u":"/media/press-releases/2022/hansa-biopharma-achieves-great-place-to-work-certification-for-the-third-consecutive-year/"},{"d":"2022-09-30","n":"Hansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Update","u":"/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-september-2022-and-business-update/"},{"d":"2022-09-30","n":"Hansa Biopharma: Increase of the number of shares and votes","u":"/media/press-releases/2022/hansa-biopharma-increase-of-the-number-of-shares-and-votes/"},{"d":"2022-08-10","n":"European Society for Organ Transplantation’s (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International","u":"/media/press-releases/2022/european-society-for-organ-transplantations-esot-guidelines-for-desensitization-treatment-of-highly-sensitized-kidney-transplant-patients-published-in-transplant-international/"},{"d":"2022-07-19","n":"Hansa Biopharma half year report 2022","u":"/media/press-releases/2022/hansa-biopharma-half-year-report-2022/"},{"d":"2022-07-18","n":"Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform","u":"/media/press-releases/2022/hansa-biopharma-announces-70-million-non-dilutive-product-finance-transaction-with-novaquest-to-support-continued-development-of-the-companys-antibody-cleaving-enzyme-technology-platform/"},{"d":"2022-07-11","n":"Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-announces-first-patient-treated-in-the-post-authorization-efficacy-study-paes-of-idefirix-imlifidase-in-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-06-30","n":"Increase of the number of votes in Hansa Biopharma","u":"/media/press-releases/2022/increase-of-the-number-of-votes-in-hansa-biopharma/"},{"d":"2022-06-30","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2022/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2022-06-30","n":"Hansa Biopharma to host conference call to provide half year results for January-June 2022 and Business Update","u":"/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-half-year-results-for-january-june-2022-and-business-update/"},{"d":"2022-06-16","n":"NICE recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/nice-recommends-use-of-hansa-biopharmas-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-05-30","n":"Hansa Biopharma: Notice to Annual General Meeting","u":"/media/press-releases/2022/hansa-biopharma-notice-to-annual-general-meeting/"},{"d":"2022-05-30","n":"The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022","u":"/media/press-releases/2022/the-nomination-committee-in-hansa-biopharma-proposes-peter-nicklin-as-new-chair-of-the-board-of-directors-at-the-annual-general-meeting-2022/"},{"d":"2022-05-23","n":"Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation","u":"/media/press-releases/2022/hansa-biopharma-completes-enrollment-in-imlifidase-phase-2-study-in-antibody-mediated-rejection-amr-episodes-post-kidney-transplantation/"},{"d":"2022-05-13","n":"Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation","u":"/media/press-releases/2022/hansa-biopharma-announces-temporary-marketing-authorization-in-switzerland-for-idefirix-imlifidase-in-kidney-transplantation/"},{"d":"2022-04-21","n":"Hansa Biopharma interim report January – March 2022","u":"/media/press-releases/2022/hansa-biopharma-interim-report-january--march-2022/"},{"d":"2022-04-20","n":"Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-granted-added-benefit-asmr-3-by-french-transparency-commission-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-04-19","n":"Hansa Biopharma announces U.S. FDA acceptance of Investigational New Drug (IND) application for Phase 3 study of imlifidase in anti-GBM disease","u":"/media/press-releases/2022/hansa-biopharma-announces-us-fda-acceptance-of-investigational-new-drug-ind-application-for-phase-3-study-of-imlifidase-in-anti-gbm-disease/"},{"d":"2022-04-08","n":"Hansa Biopharma to host conference call to provide interim results for January-March 2022 and Business Update","u":"/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-march-2022-and-business-update/"},{"d":"2022-04-07","n":"Hansa Biopharma publishes Annual Report 2021","u":"/media/press-releases/2022/hansa-biopharma-publishes-annual-report-2021/"},{"d":"2022-03-28","n":"Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix[®] (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-and-medison-pharma-announce-marketing-authorization-in-israel-for-idefirix-imlifidase-for-desensitization-treatment-of-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-03-15","n":"Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-and-german-payer-head-association-agree-on-reimbursement-price-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-03-08","n":"Key data demonstrating the potential of Hansa Biopharma’s imlifidase to significantly alter course of anti-GBM disease published in JASN","u":"/media/press-releases/2022/key-data-demonstrating-the-potential-of-hansa-biopharmas-imlifidase-to-significantly-alter-course-of-anti-gbm-disease-published-in-jasn/"},{"d":"2022-02-25","n":"Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2022/hansa-biopharma-announces-positive-early-access-decision-by-french-haute-autorite-de-sante-to-use-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2022-02-03","n":"Hansa Biopharma year-end report 2021","u":"/media/press-releases/2022/hansa-biopharma-year-end-report-2021/"},{"d":"2022-01-20","n":"Hansa Biopharma to host conference call to provide Year-End report for 2021 and Business Update","u":"/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-for-2021-and-business-update/"},{"d":"2022-01-09","n":"Hansa Biopharma provides business update including certain key financials","u":"/media/press-releases/2022/hansa-biopharma-provides-business-update-including-certain-key-financials/"},{"d":"2022-01-03","n":"Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease","u":"/media/press-releases/2022/hansa-biopharma-enters-into-agreement-with-askbio-to-evaluate-feasibility-of-imlifidase-as-pre-treatment-ahead-of-gene-therapy-in-pompe-disease/"},{"d":"2021-12-30","n":"Increase of the number of shares and votes in Hansa Biopharma AB","u":"/media/press-releases/2021/increase-of-the-number-of-shares-and-votes-in-hansa-biopharma-ab/"},{"d":"2021-12-29","n":"Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients","u":"/media/press-releases/2021/hansa-biopharma-enrolls-first-patient-in-us-randomized-controlled-pivotal-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/"},{"d":"2021-12-09","n":"Hansa Biopharma: Issue and repurchase of class C shares for incentive programs","u":"/media/press-releases/2021/hansa-biopharma-issue-and-repurchase-of-class-c-shares-for-incentive-programs/"},{"d":"2021-12-07","n":"Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa’s desensitization treatment for kidney transplant in Central Eastern Europe and Israel","u":"/media/press-releases/2021/hansa-biopharma-and-medison-pharma-announce-multiregional-commercialization-partnership-for-hansas-desensitization-treatment-for-kidney-transplant-in-central-eastern-europe-and-israel/"},{"d":"2021-11-15","n":"Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA","u":"/media/press-releases/2021/hansa-biopharma-to-initiate-phase-3-study-of-imlifidase-to-treat-anti-glomerular-basement-membrane-anti-gbm-disease-after-successful-pre-ind-meeting-with-us-fda/"},{"d":"2021-11-12","n":"Hansa Biopharma Nomination Committee formed","u":"/media/press-releases/2021/hansa-biopharma-nomination-committee-formed/"},{"d":"2021-11-08","n":"Hansa Biopharma announces it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential U.S. IPO","u":"/media/press-releases/2021/hansa-biopharma-announces-it-has-confidentially-submitted-a-draft-registration-statement-on-form-f-1-to-the-us-sec-relating-to-a-potential-us-ipo/"},{"d":"2021-10-21","n":"Hansa Biopharma interim report Jan-Sept 2021","u":"/media/press-releases/2021/hansa-biopharma-interim-report-jan-sept-2021/"},{"d":"2021-10-07","n":"Hansa Biopharma to host conference call to provide interim results for January-September 2021 and Business Update","u":"/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-september-2021-and-business-update/"},{"d":"2021-09-01","n":"Hansa Biopharma presented new data on imlifidase at the European Society for Organ Transplantation (ESOT) Congress","u":"/media/press-releases/2021/hansa-biopharma-presented-new-data-on-imlifidase-at-the-european-society-for-organ-transplantation-esot-congress/"},{"d":"2021-08-31","n":"Hansa Biopharma announces participation in Fall investor conferences and provides updated financial calendar","u":"/media/press-releases/2021/hansa-biopharma-announces-participation-in-fall-investor-conferences-and-provides-updated-financial-calendar/"},{"d":"2021-08-25","n":"Hansa Biopharma achieves Great Place to Work certification for second consecutive year","u":"/media/press-releases/2021/hansa-biopharma-achieves-great-place-to-work-certification-for-second-consecutive-year/"},{"d":"2021-08-02","n":"Hansa Biopharma announces reimbursement in the Netherlands of Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2021/hansa-biopharma-announces-reimbursement-in-the-netherlands-of-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2021-07-15","n":"Hansa Biopharma interim report Jan-June 2021","u":"/media/press-releases/2021/hansa-biopharma-interim-report-jan-june-2021/"},{"d":"2021-07-09","n":"Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation","u":"/media/press-releases/2021/hansa-biopharma-announces-long-term-follow-up-data-demonstrating-3-year-graft-survival-of-84-after-imlifidase-treatment-and-transplantation/"},{"d":"2021-07-01","n":"Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update","u":"/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-first-half-2021-and-business-update/"},{"d":"2021-06-28","n":"Hansa Biopharma announces decision by Swedish New Therapies Council to recommend use of Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","u":"/media/press-releases/2021/hansa-biopharma-announces-decision-by-swedish-new-therapies-council-to-recommend-use-of-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/"},{"d":"2021-06-23","n":"Hansa Biopharma announces study design for a US randomized, controlled trial of imlifidase in highly sensitized kidney transplant patients","u":"/media/press-releases/2021/hansa-biopharma-announces-study-design-for-a-us-randomized-controlled-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/"},{"d":"2021-05-12","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2021/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2021-04-22","n":"Hansa Biopharma interim report Jan-Mar 2021","u":"/media/press-releases/2021/hansa-biopharma-interim-report-jan-mar-2021/"},{"d":"2021-04-14","n":"Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update","u":"/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-interim-results-from-q1-2021-and-business-update/"},{"d":"2021-04-09","n":"Hansa Biopharma: Notice to Annual General Meeting","u":"/media/press-releases/2021/hansa-biopharma-notice-to-annual-general-meeting/"},{"d":"2021-04-08","n":"Hansa Biopharma publishes Annual Report 2020","u":"/media/press-releases/2021/hansa-biopharma-publishes-annual-report-2020/"},{"d":"2021-03-29","n":"Hansa Biopharma enters preclinical research collaboration with argenx","u":"/media/press-releases/2021/hansa-biopharma-enters-preclinical-research-collaboration-with-argenx/"},{"d":"2021-03-01","n":"Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development","u":"/media/press-releases/2021/hansa-biopharma-appoints-dr-magnus-korsgren-as-head-of-research--development/"},{"d":"2021-02-04","n":"Hansa Biopharma year-end report Jan-Dec 2020","u":"/media/press-releases/2021/hansa-biopharma-year-end-report-jan-dec-2020/"},{"d":"2021-01-27","n":"Hansa Biopharma to host conference call to provide Year-End report 2020 and Business Update","u":"/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-2020-and-business-update/"},{"d":"2021-01-11","n":"Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference","u":"/media/press-releases/2021/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference/"},{"d":"2020-12-23","n":"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference","u":"/media/press-releases/2020/hansa-biopharma-to-present-at-the-39th-annual-jp-morgan-healthcare-conference/"},{"d":"2020-11-02","n":"Hansa Biopharma Nomination Committee formed","u":"/media/press-releases/2020/hansa-biopharma-nomination-committee-formed/"},{"d":"2020-10-22","n":"Hansa Biopharma interim report Jan-Sep 2020","u":"/media/press-releases/2020/hansa-biopharma-interim-report-jan-sep-2020/"},{"d":"2020-09-24","n":"Hansa Biopharm announces positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease","u":"/media/press-releases/2020/hansa-biopharm-announces-positive-high-level-data-from-investigator-initiated-phase-2-trial-with-imlifidase-to-treat-anti-gbm-disease/"},{"d":"2020-09-17","n":"Hansa Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen","u":"/media/press-releases/2020/hansa-biopharma-to-host-capital-markets-day-on-thursday-october-29-2020-in-copenhagen/"},{"d":"2020-09-11","n":"Hansa Biopharma AB certified as a Great Place to Work[® ]","u":"/media/press-releases/2020/hansa-biopharma-ab-certified-as-a-great-place-to-work-/"},{"d":"2020-09-01","n":"Hansa Biopharma provides updated guidance on its clinical programs","u":"/media/press-releases/2020/hansa-biopharma-provides-updated-guidance-on-its-clinical-programs/"},{"d":"2020-08-31","n":"Hansa Biopharma announces participation in Fall conferences and an updated financial calendar","u":"/media/press-releases/2020/hansa-biopharma-announces-participation-in-fall-conferences-and-an-updated-financial-calendar/"},{"d":"2020-08-26","n":"The EU Commission grants conditional approval for Idefirix[TM] (imlifidase) in highly sensitized kidney transplant patients in the European Union","u":"/media/press-releases/2020/the-eu-commission-grants-conditional-approval-for-idefirixtm-imlifidase-in-highly-sensitized-kidney-transplant-patients-in-the-european-union/"},{"d":"2020-07-31","n":"Hansa Biopharma announces increase in number of shares and votes","u":"/media/press-releases/2020/hansa-biopharma-announces-increase-in-number-of-shares-and-votes/"},{"d":"2020-07-16","n":"Hansa Biopharma expands the leadership team with the appointment of Katja Margell as new Head of Corporate Communications","u":"/media/press-releases/2020/hansa-biopharma-expands-the-leadership-team-with-the-appointment-of-katja-margell-as-new-head-of-corporate-communications/"},{"d":"2020-07-16","n":"Hansa Biopharma interim report Jan-Jun 2020","u":"/media/press-releases/2020/hansa-biopharma-interim-report-jan-jun-2020/"},{"d":"2020-07-08","n":"Hansa Biopharma announces successful completion of SEK 1.1bn (USD 121m) placing of newly issued shares","u":"/media/press-releases/2020/hansa-biopharma-announces-successful-completion-of-sek-11bn-usd-121m-placing-of-newly-issued-shares/"},{"d":"2020-07-08","n":"Hansa Biopharma announces intention to carry out a placing of new ordinary shares","u":"/media/press-releases/2020/hansa-biopharma-announces-intention-to-carry-out-a-placing-of-new-ordinary-shares/"},{"d":"2020-07-02","n":"Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications","u":"/media/press-releases/2020/hansa-biopharma-announces-exclusive-agreement-with-sarepta-therapeutics-to-develop-and-promote-imlifidase-as-pre-treatment-ahead-of-gene-therapy-in-select-indications/"},{"d":"2020-06-30","n":"Hansa Biopharma to host conference call to provide interim results for the first half of 2020 and business update","u":"/media/press-releases/2020/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-half-of-2020-and-business-update/"},{"d":"2020-06-25","n":"Hansa Biopharma receives positive CHMP opinion for Idefirix[TM] (imlifidase) for kidney transplant in EU","u":"/media/press-releases/2020/hansa-biopharma-receives-positive-chmp-opinion-for-idefirixtm-imlifidase-for-kidney-transplant-in-eu/"},{"d":"2020-06-23","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2020/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2020-05-29","n":"Hansa Biopharma appoints Achim Kaufhold as CMO to support the expansion outside transplantation","u":"/media/press-releases/2020/hansa-biopharma-appoints-achim-kaufhold-as-cmo-to-support-the-expansion-outside-transplantation/"},{"d":"2020-05-25","n":"Hansa Biopharma submits responses to outstanding questions from EMA on May 26. Review is on track; an opinion from CHMP is expected by end of June.","u":"/media/press-releases/2020/hansa-biopharma-submits-responses-to-outstanding-questions-from-ema-on-may-26-review-is-on-track-an-opinion-from-chmp-is-expected-by-end-of-june/"},{"d":"2020-05-20","n":"Hansa Biopharma announces upcoming presentations including a late breaking poster presentation at the 2020 American Transplant Congress","u":"/media/press-releases/2020/hansa-biopharma-announces-upcoming-presentations-including-a-late-breaking-poster-presentation-at-the-2020-american-transplant-congress/"},{"d":"2020-05-20","n":"Notice to Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2020/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2020-05-13","n":"Hansa Biopharma to participate in five upcoming investor conferences during May and June","u":"/media/press-releases/2020/hansa-biopharma-to-participate-in-five-upcoming-investor-conferences-during-may-and-june/"},{"d":"2020-04-28","n":"Hansa Biopharma interim report Jan-Mar 2020. EMA process on track; an opinion from the CHMP is expected in the second quarter 2020.","u":"/media/press-releases/2020/hansa-biopharma-interim-report-jan-mar-2020-ema-process-on-track-an-opinion-from-the-chmp-is-expected-in-the-second-quarter-2020/"},{"d":"2020-04-15","n":"Hansa Biopharma to host conference call to provide interim results for the first quarter of 2020 and business update","u":"/media/press-releases/2020/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-quarter-of-2020-and-business-update/"},{"d":"2020-04-02","n":"Hansa Biopharma publishes Annual Report 2019","u":"/media/press-releases/2020/hansa-biopharma-publishes-annual-report-2019/"},{"d":"2020-03-06","n":"Hansa Biopharma announces long term follow-up data that demonstrates 2-year graft survival of 89% after imlifdase treatment and transplantation","u":"/media/press-releases/2020/hansa-biopharma-announces-long-term-follow-up-data-that-demonstrates-2-year-graft-survival-of-89-after-imlifdase-treatment-and-transplantation/"},{"d":"2020-02-25","n":"Hansa Biopharma to participate in two upcoming investor conferences","u":"/media/press-releases/2020/hansa-biopharma-to-participate-in-two-upcoming-investor-conferences/"},{"d":"2020-02-06","n":"Hansa Biopharma Year-End Report 2019","u":"/media/press-releases/2020/hansa-biopharma-year-end-report-2019/"},{"d":"2020-01-27","n":"Hansa Biopharma completes enrollment in anti-GBM","u":"/media/press-releases/2020/hansa-biopharma-completes-enrollment-in-anti-gbm/"},{"d":"2020-01-22","n":"Hansa Biopharma to host conference call to provide Year-End report 2019 and Business Update","u":"/media/press-releases/2020/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-2019-and-business-update/"},{"d":"2020-01-12","n":"Hansa Biopharma provides business update ahead of the JP Morgan Global Healthcare Conference","u":"/media/press-releases/2020/hansa-biopharma-provides-business-update-ahead-of-the-jp-morgan-global-healthcare-conference/"},{"d":"2019-12-13","n":"Hansa Biopharma has agreed with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S.","u":"/media/press-releases/2019/hansa-biopharma-has-agreed-with-the-fda-on-a-regulatory-path-forward-for-imlifidase-in-kidney-transplantation-of-highly-sensitized-patients-in-the-us/"},{"d":"2019-11-19","n":"Hansa Biopharma Nomination Committee formed","u":"/media/press-releases/2019/hansa-biopharma-nomination-committee-formed/"},{"d":"2019-10-31","n":"Hansa Biopharma Interim Report January–September 2019","u":"/media/press-releases/2019/hansa-biopharma-interim-report-januaryseptember-2019/"},{"d":"2019-10-11","n":"Hansa Biopharma to host conference call to provide interim results for the first nine months of 2019 and business update","u":"/media/press-releases/2019/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-nine-months-of-2019-and-business-update/"},{"d":"2019-09-30","n":"Increase of number of shares and votes in Hansa Biopharma AB","u":"/media/press-releases/2019/increase-of-number-of-shares-and-votes-in-hansa-biopharma-ab/"},{"d":"2019-09-25","n":"Hansa Biopharma confirms follow-up meeting with FDA","u":"/media/press-releases/2019/hansa-biopharma-confirms-follow-up-meeting-with-fda/"},{"d":"2019-09-18","n":"Hansa Biopharma: Positive results presented at ESOT; imlifidase enabled  transplantation in 46 sensitized patients","u":"/media/press-releases/2019/hansa-biopharma-positive-results-presented-at-esot-imlifidase-enabled--transplantation-in-46-sensitized-patients/"},{"d":"2019-09-02","n":"Hansa Biopharma: Issue and re-purchase of class C shares for incentive programme","u":"/media/press-releases/2019/hansa-biopharma-issue-and-re-purchase-of-class-c-shares-for-incentive-programme/"},{"d":"2019-08-30","n":"Hansa Biopharma: New imlifidase data presented at ESOT, Copenhagen","u":"/media/press-releases/2019/hansa-biopharma-new-imlifidase-data-presented-at-esot-copenhagen/"},{"d":"2019-08-21","n":"Hansa Biopharma to participate in three upcoming investor conferences","u":"/media/press-releases/2019/hansa-biopharma-to-participate-in-three-upcoming-investor-conferences/"},{"d":"2019-07-18","n":"Hansa Biopharma Interim Report January–June 2019","u":"/media/press-releases/2019/hansa-biopharma-interim-report-januaryjune-2019/"},{"d":"2019-07-05","n":"Hansa Biopharma to Host Conference Call to Provide Second Quarter 2019 Business Update","u":"/media/press-releases/2019/hansa-biopharma-to-host-conference-call-to-provide-second-quarter-2019-business-update/"},{"d":"2019-06-07","n":"Plenary Presentation at the 2019 American Transplant Congress Demonstrates Significant Reduction in Time on the Waitlist for Patients Treated with Imlifidase Compared to Matched Controls","u":"/media/press-releases/2019/plenary-presentation-at-the-2019-american-transplant-congress-demonstrates-significant-reduction-in-time-on-the-waitlist-for-patients-treated-with-imlifidase-compared-to-matched-controls/"},{"d":"2019-05-22","n":"Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2019/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2019-05-13","n":"Hansa Biopharma to participate in UBS Global Healthcare Conference and RBC Capital Markets Global Healthcare Conference in New York City","u":"/media/press-releases/2019/hansa-biopharma-to-participate-in-ubs-global-healthcare-conference-and-rbc-capital-markets-global-healthcare-conference-in-new-york-city/"},{"d":"2019-05-02","n":"Hansa Biopharma Announces Upcoming Presentations at the 2019 American Transplant Congress","u":"/media/press-releases/2019/hansa-biopharma-announces-upcoming-presentations-at-the-2019-american-transplant-congress/"},{"d":"2019-04-29","n":"Hansa Biopharma expands leadership team with dedicated roles for Corporate Communications, Investor Relations and Business Development","u":"/media/press-releases/2019/hansa-biopharma-expands-leadership-team-with-dedicated-roles-for-corporate-communications-investor-relations-and-business-development/"},{"d":"2019-04-29","n":"Hansa Biopharma Interim Report January–March 2019","u":"/media/press-releases/2019/hansa-biopharma-interim-report-januarymarch-2019/"},{"d":"2019-04-23","n":"Hansa Biopharma to Host Conference Call to Provide First Quarter 2019 Business Update","u":"/media/press-releases/2019/hansa-biopharma-to-host-conference-call-to-provide-first-quarter-2019-business-update/"},{"d":"2019-04-17","n":"Notice to Annual General Meeting in Hansa Biopharma AB (publ)","u":"/media/press-releases/2019/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/"},{"d":"2019-04-15","n":"Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome","u":"/media/press-releases/2019/hansa-biopharma-receives-ethics-and-regulatory-clearance-to-start-phase-2-study-of-imlifidase-in-guillain-barre-syndrome/"},{"d":"2019-04-15","n":"Hansa Biopharma divests its equity holding in Genovis","u":"/media/press-releases/2019/hansa-biopharma-divests-its-equity-holding-in-genovis/"},{"d":"2019-04-15","n":"Hansa Biopharma publishes the Annual Report for 2018","u":"/media/press-releases/2019/hansa-biopharma-publishes-the-annual-report-for-2018/"},{"d":"2019-03-26","n":"Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation","u":"/media/press-releases/2019/hansa-biopharma-receives-ethics-and-regulatory-clearance-to-start-phase-2-study-of-imlifidase-in-acute-antibody-mediated-rejection-in-kidney-transplantation/"},{"d":"2019-03-21","n":"Hansa Biopharma Announces Selection of NiceR Lead Candidate","u":"/media/press-releases/2019/hansa-biopharma-announces-selection-of-nicer-lead-candidate/"},{"d":"2019-03-06","n":"Hansa Biopharma to Present at the Cowen 39th Annual Health Care Conference","u":"/media/press-releases/2019/hansa-biopharma-to-present-at-the-cowen-39th-annual-health-care-conference/"},{"d":"2019-03-01","n":"Hansa Biopharma Announces European Medicines Agency Accepts Marketing Authorization Application for IDEFIRIX™ (imlifidase)","u":"/media/press-releases/2019/hansa-biopharma-announces-european-medicines-agency-accepts-marketing-authorization-application-for-idefirix-imlifidase/"},{"d":"2019-02-28","n":"Increase of number of shares and votes in Hansa Biopharma AB (publ)","u":"/media/press-releases/2019/increase-of-number-of-shares-and-votes-in-hansa-biopharma-ab-publ/"},{"d":"2019-02-08","n":"Hansa Biopharma Year-End Report 2018","u":"/media/press-releases/2019/hansa-biopharma-year-end-report-2018/"},{"d":"2019-02-07","n":"Hansa Biopharma appoints Donato Spota as new Chief Financial Officer","u":"/media/press-releases/2019/hansa-biopharma-appoints-donato-spota-as-new-chief-financial-officer/"},{"d":"2019-01-31","n":"Hansa Medical to Host Conference Call to Provide Year-End Report 2018 Business Update","u":"/media/press-releases/2019/hansa-medical-to-host-conference-call-to-provide-year-end-report-2018-business-update/"},{"d":"2019-01-31","n":"Increase of number of votes in Hansa Medical AB (publ)","u":"/media/press-releases/2019/increase-of-number-of-votes-in-hansa-medical-ab-publ/"},{"d":"2019-01-18","n":"Hansa Medical Announces Appointment of Anne Säfström Lanner as Vice President, Global Human Resources","u":"/media/press-releases/2019/hansa-medical-announces-appointment-of-anne-safstrom-lanner-as-vice-president-global-human-resources/"},{"d":"2019-01-15","n":"Hansa Medical AB Provides Regulatory Update for Imlifidase in Kidney Transplantation","u":"/media/press-releases/2019/hansa-medical-ab-provides-regulatory-update-for-imlifidase-in-kidney-transplantation/"},{"d":"2018-12-20","n":"Hansa Medical AB to change name to Hansa Biopharma AB","u":"/media/press-releases/2018/hansa-medical-ab-to-change-name-to-hansa-biopharma-ab/"},{"d":"2018-12-11","n":"Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2018/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2018-11-30","n":"Hansa Medical AB Announces Increase in Number of Shares and Votes","u":"/media/press-releases/2018/hansa-medical-ab-announces-increase-in-number-of-shares-and-votes/"},{"d":"2018-11-21","n":"Hansa Medical AB to Present at the Evercore ISI HealthConX Conference","u":"/media/press-releases/2018/hansa-medical-ab-to-present-at-the-evercore-isi-healthconx-conference/"},{"d":"2018-11-09","n":"Notice of Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2018/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2018-11-01","n":"Hansa Medical Interim report July – September 2018","u":"/media/press-releases/2018/hansa-medical-interim-report-july--september-2018/"},{"d":"2018-10-31","n":"Increase of Number of Shares and Votes in Hansa Medical AB (publ)","u":"/media/press-releases/2018/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ/"},{"d":"2018-10-29","n":"Bulletin from the Extraordinary General Meeting of Hansa Medical AB","u":"/media/press-releases/2018/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab/"},{"d":"2018-10-26","n":"Presentation at ASN Kidney Week 2018 Highlights Stable Renal Function at up to 24 Months Following Transplantation Enabled by Imlifidase","u":"/media/press-releases/2018/presentation-at-asn-kidney-week-2018-highlights-stable-renal-function-at-up-to-24-months-following-transplantation-enabled-by-imlifidase/"},{"d":"2018-10-25","n":"Hansa Medical's Nomination Committee for the AGM 2019 Appointed and 2019 Financial Calendar Published","u":"/media/press-releases/2018/hansa-medicals-nomination-committee-for-the-agm-2019-appointed-and-2019-financial-calendar-published/"},{"d":"2018-10-25","n":"Hansa Medical to Report Interim Results for the Third Quarter of 2018 and Host Conference Call and Webcast","u":"/media/press-releases/2018/hansa-medical-to-report-interim-results-for-the-third-quarter-of-2018-and-host-conference-call-and-webcast/"},{"d":"2018-10-24","n":"Hansa Medical Receives Positive Opinion for Orphan Drug Designation in the EU for Imlifidase for Anti-GBM Disease","u":"/media/press-releases/2018/hansa-medical-receives-positive-opinion-for-orphan-drug-designation-in-the-eu-for-imlifidase-for-anti-gbm-disease/"},{"d":"2018-10-17","n":"Hansa Medical Receives FDA Fast Track Designation for Imlifidase for Transplantation","u":"/media/press-releases/2018/hansa-medical-receives-fda-fast-track-designation-for-imlifidase-for-transplantation/"},{"d":"2018-10-05","n":"Notice of Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2018/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ-2018-10-05/"},{"d":"2018-09-27","n":"Hansa Medical Reports Positive Final Top Line Results from Two Phase 2 Studies of Imlifidase for Kidney Transplantation","u":"/media/press-releases/2018/hansa-medical-reports-positive-final-top-line-results-from-two-phase-2-studies-of-imlifidase-for-kidney-transplantation/"},{"d":"2018-09-17","n":"Hansa Medical Announces Appointment of Vincenza Nigro as Vice President, Global Medical Affairs","u":"/media/press-releases/2018/hansa-medical-announces-appointment-of-vincenza-nigro-as-vice-president-global-medical-affairs/"},{"d":"2018-09-06","n":"Issue and repurchase of class C shares for incentive program","u":"/media/press-releases/2018/issue-and-repurchase-of-class-c-shares-for-incentive-program/"},{"d":"2018-08-06","n":"Hansa Medical initiates follow up study of patients treated with lead candidate imlifidase (IdeS) prior to kidney transplantation","u":"/media/press-releases/2018/hansa-medical-initiates-follow-up-study-of-patients-treated-with-lead-candidate-imlifidase-ides-prior-to-kidney-transplantation/"},{"d":"2018-07-31","n":"Increase of number of shares and votes in Hansa Medical AB (publ)","u":"/media/press-releases/2018/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ-2018-07-31/"},{"d":"2018-07-19","n":"Hansa Medical Interim report April – June 2018","u":"/media/press-releases/2018/hansa-medical-interim-report-april--june-2018/"},{"d":"2018-07-12","n":"Hansa Medical to Host Conference Call to Provide Second Quarter 2018 Business Update","u":"/media/press-releases/2018/hansa-medical-to-host-conference-call-to-provide-second-quarter-2018-business-update/"},{"d":"2018-07-09","n":"Hansa Medical lead candidate imlifidase (IdeS) granted orphan drug designation by the FDA for anti-GBM antibody disease","u":"/media/press-releases/2018/hansa-medical-lead-candidate-imlifidase-ides-granted-orphan-drug-designation-by-the-fda-for-anti-gbm-antibody-disease/"},{"d":"2018-06-29","n":"Increase of number of shares in Hansa Medical AB (publ)","u":"/media/press-releases/2018/increase-of-number-of-shares-in-hansa-medical-ab-publ/"},{"d":"2018-06-15","n":"Hansa Medical’s warrant program TO2015 has opened for exercise and subscription of shares","u":"/media/press-releases/2018/hansa-medicals-warrant-program-to2015-has-opened-for-exercise-and-subscription-of-shares/"},{"d":"2018-06-06","n":"Presentation at the 2018 American Transplant Congress highlights the long-term risk-benefit profile of imlifidase (IdeS) in kidney transplantation","u":"/media/press-releases/2018/presentation-at-the-2018-american-transplant-congress-highlights-the-long-term-risk-benefit-profile-of-imlifidase-ides-in-kidney-transplantation/"},{"d":"2018-05-30","n":"Long-term follow up data from investigator-initiated Phase II study with imlifidase (IdeS) to be presented at 2018 American Transplant Congress (ATC)","u":"/media/press-releases/2018/long-term-follow-up-data-from-investigator-initiated-phase-ii-study-with-imlifidase-ides-to-be-presented-at-2018-american-transplant-congress-atc/"},{"d":"2018-05-29","n":"Bulletin from the Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2018/bulletin-from-the-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2018-04-25","n":"Hansa Medical Interim Report January–March 2018","u":"/media/press-releases/2018/hansa-medical-interim-report-januarymarch-2018/"},{"d":"2018-04-25","n":"Notice to Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2018/notice-to-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2018-04-18","n":"Hansa Medical to Host Conference Call to Provide First Quarter 2018 Business Update","u":"/media/press-releases/2018/hansa-medical-to-host-conference-call-to-provide-first-quarter-2018-business-update/"},{"d":"2018-04-11","n":"Hansa Medical publishes the Annual Report for 2017","u":"/media/press-releases/2018/hansa-medical-publishes-the-annual-report-for-2017/"},{"d":"2018-03-21","n":"The American Journal of Transplantation publishes results from Hansa Medical's first Phase II study with IdeS","u":"/media/press-releases/2018/the-american-journal-of-transplantation-publishes-results-from-hansa-medicals-first-phase-ii-study-with-ides/"},{"d":"2018-03-20","n":"Søren Tulstrup appointed new President and CEO of Hansa Medical","u":"/media/press-releases/2018/soren-tulstrup-appointed-new-president-and-ceo-of-hansa-medical/"},{"d":"2018-02-16","n":"Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barré syndrome","u":"/media/press-releases/2018/hansa-medical-receives-fda-orphan-drug-designation-for-ides-and-the-treatment-of-guillain-barre-syndrome/"},{"d":"2018-02-14","n":"Intermediate evaluation of a sub-population in the Highdes study demonstrates good kidney function 5.5 months (median) post transplantation","u":"/media/press-releases/2018/intermediate-evaluation-of-a-sub-population-in-the-highdes-study-demonstrates-good-kidney-function-55-months-median-post-transplantation/"},{"d":"2018-02-14","n":"Hansa Medical Year-End Report 2017","u":"/media/press-releases/2018/hansa-medical-year-end-report-2017/"},{"d":"2018-02-07","n":"Hansa Medical to Host Conference Call to Provide Year-End Report 2017 Business Update","u":"/media/press-releases/2018/hansa-medical-to-host-conference-call-to-provide-year-end-report-2017-business-update/"},{"d":"2018-01-31","n":"Increase of number of votes in Hansa Medical AB (publ)","u":"/media/press-releases/2018/increase-of-number-of-votes-in-hansa-medical-ab-publ/"},{"d":"2018-01-04","n":"Completed enrollment in Hansa Medical’s international multi-center Phase II study Highdes","u":"/media/press-releases/2018/completed-enrollment-in-hansa-medicals-international-multi-center-phase-ii-study-highdes/"},{"d":"2018-01-03","n":"Finalized enrollment in US Phase II study with IdeS in highly sensitized patients","u":"/media/press-releases/2018/finalized-enrollment-in-us-phase-ii-study-with-ides-in-highly-sensitized-patients/"},{"d":"2017-12-29","n":"Increase of number of shares and votes in Hansa Medical AB (publ)","u":"/media/press-releases/2017/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ/"},{"d":"2017-12-22","n":"Bulletin from the extraordinary general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2017/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2017-11-30","n":"Notice of Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2017/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2017-11-17","n":"Hansa Medical's Nomination Committee for the AGM 2018 appointed","u":"/media/press-releases/2017/hansa-medicals-nomination-committee-for-the-agm-2018-appointed/"},{"d":"2017-11-14","n":"Hansa Medical Interim report July – September 2017","u":"/media/press-releases/2017/hansa-medical-interim-report-july--september-2017/"},{"d":"2017-11-09","n":"The time point for Hansa Medical’s Third Quarter 2017 Business Update Conference Call has been changed","u":"/media/press-releases/2017/the-time-point-for-hansa-medicals-third-quarter-2017-business-update-conference-call-has-been-changed/"},{"d":"2017-11-08","n":"Hansa Medical announces sudden death of CEO Göran Arvidson","u":"/media/press-releases/2017/hansa-medical-announces-sudden-death-of-ceo-goran-arvidson/"},{"d":"2017-11-07","n":"Hansa Medical to Host Conference Call to Provide Third Quarter 2017 Business Update","u":"/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-third-quarter-2017-business-update/"},{"d":"2017-10-03","n":"Hansa Medical’s Capital Market Days provide an update on number of patients included in the company’s kidney transplantation and anti-GBM studies","u":"/media/press-releases/2017/hansa-medicals-capital-market-days-provide-an-update-on-number-of-patients-included-in-the-companys-kidney-transplantation-and-anti-gbm-studies/"},{"d":"2017-10-03","n":"Hansa Medical’s Capital Market Days provide an update on number of patients included in the company’s kidney transplantation and anti-GBM studies","u":"/media/press-releases/2017/hansa-medicals-capital-market-days-provide-an-update-on-number-of-patients-included-in-the-companys-kidney-transplantation-and-anti-gbm-studies-2017-10-03/"},{"d":"2017-09-22","n":"Hansa Medical announces agenda for Capital Markets Days in Stockholm & London","u":"/media/press-releases/2017/hansa-medical-announces-agenda-for-capital-markets-days-in-stockholm--london/"},{"d":"2017-08-23","n":"SAVE THE DATE: Tuesday 3 & Wednesday 4 October 2017, Hansa Medical’s Capital Markets Days, Stockholm & London","u":"/media/press-releases/2017/save-the-date-tuesday-3--wednesday-4-october-2017-hansa-medicals-capital-markets-days-stockholm--london/"},{"d":"2017-08-02","n":"The New England Journal of Medicine publishes results from Phase II studies of Hansa Medical’s lead candidate IdeS in highly sensitized patients","u":"/media/press-releases/2017/the-new-england-journal-of-medicine-publishes-results-from-phase-ii-studies-of-hansa-medicals-lead-candidate-ides-in-highly-sensitized-patients/"},{"d":"2017-07-20","n":"Hansa Medical Interim report April-June 2017","u":"/media/press-releases/2017/hansa-medical-interim-report-april-june-2017/"},{"d":"2017-07-13","n":"Hansa Medical to Host Conference Call to Provide Second Quarter 2017 Business Update","u":"/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-second-quarter-2017-business-update/"},{"d":"2017-06-20","n":"First patient treated in Phase II study with IdeS in anti-GBM antibody disease","u":"/media/press-releases/2017/first-patient-treated-in-phase-ii-study-with-ides-in-anti-gbm-antibody-disease/"},{"d":"2017-06-07","n":"Hansa Medical to present at Jefferies 2017 Global Healthcare Conference","u":"/media/press-releases/2017/hansa-medical-to-present-at-jefferies-2017-global-healthcare-conference/"},{"d":"2017-05-31","n":"Increase of number of shares and votes in Hansa Medical AB (publ)","u":"/media/press-releases/2017/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ-2017-05-31/"},{"d":"2017-05-24","n":"Resolutions adopted at the annual general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2017/resolutions-adopted-at-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2017-05-23","n":"Published preclinical results confirm IdeS potential in cancer immunotherapy","u":"/media/press-releases/2017/published-preclinical-results-confirm-ides-potential-in-cancer-immunotherapy/"},{"d":"2017-05-19","n":"IdeS selected for EMA Priority Medicines (PRIME) scheme","u":"/media/press-releases/2017/ides-selected-for-ema-priority-medicines-prime-scheme/"},{"d":"2017-05-12","n":"Lead candidate IdeS discussed in FDA workshop","u":"/media/press-releases/2017/lead-candidate-ides-discussed-in-fda-workshop/"},{"d":"2017-04-27","n":"Issue and repurchase of class C shares for incentive program","u":"/media/press-releases/2017/issue-and-repurchase-of-class-c-shares-for-incentive-program/"},{"d":"2017-04-26","n":"Interim report January – March 2017","u":"/media/press-releases/2017/interim-report-january--march-2017/"},{"d":"2017-04-26","n":"Hansa Medical publishes the Annual Report for 2016","u":"/media/press-releases/2017/hansa-medical-publishes-the-annual-report-for-2016/"},{"d":"2017-04-24","n":"NOTICE OF ANNUAL GENERAL MEETING IN Hansa Medical AB (publ)","u":"/media/press-releases/2017/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2017-04-19","n":"Hansa Medical to Host Conference Call to Provide First Quarter 2017 Business Update","u":"/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-first-quarter-2017-business-update/"},{"d":"2017-03-31","n":"Hansa Medical appoints Sam Agus as new Chief Medical Officer","u":"/media/press-releases/2017/hansa-medical-appoints-sam-agus-as-new-chief-medical-officer/"},{"d":"2017-03-29","n":"Top-line clinical results from US study with lead candidate IdeS to be presented at the American Transplant Congress","u":"/media/press-releases/2017/top-line-clinical-results-from-us-study-with-lead-candidate-ides-to-be-presented-at-the-american-transplant-congress/"},{"d":"2017-03-08","n":"Hansa Medical to present at The Oppenheimer 27th Annual Healthcare Conference","u":"/media/press-releases/2017/hansa-medical-to-present-at-the-oppenheimer-27th-annual-healthcare-conference/"},{"d":"2017-02-16","n":"Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barré syndrome (GBS)","u":"/media/press-releases/2017/novel-pre-clinical-in-vivo-data-demonstrate-the-treatment-potential-of-ides-in-guillain-barre-syndrome-gbs/"},{"d":"2017-02-15","n":"Hansa Medical Year-End Report 2016","u":"/media/press-releases/2017/hansa-medical-year-end-report-2016/"},{"d":"2017-02-09","n":"Hansa Medical to Host Conference Call to Provide Fourth Quarter and Full Year 2016 Business Update","u":"/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-fourth-quarter-and-full-year-2016-business-update/"},{"d":"2016-12-21","n":"Hansa Medical announces successful completion of a Phase II clinical trial of IdeS in sensitized kidney patients","u":"/media/press-releases/2016/hansa-medical-announces-successful-completion-of-a-phase-ii-clinical-trial-of-ides-in-sensitized-kidney-patients/"},{"d":"2016-12-21","n":"Hansa Medical discontinues its Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)","u":"/media/press-releases/2016/hansa-medical-discontinues-its-phase-ii-study-in-acquired-thrombotic-thrombocytopenic-purpura-ttp/"},{"d":"2016-12-15","n":"Hansa Medical’s application for Orphan Drug Designation for IdeS in the EU receives positive opinion","u":"/media/press-releases/2016/hansa-medicals-application-for-orphan-drug-designation-for-ides-in-the-eu-receives-positive-opinion/"},{"d":"2016-11-30","n":"Increase of number of shares in Hansa Medical AB (publ)","u":"/media/press-releases/2016/increase-of-number-of-shares-in-hansa-medical-ab-publ/"},{"d":"2016-11-21","n":"Bulletin from the extraordinary general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2016/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2016-11-09","n":"Hansa Medical Interim report July – September 2016","u":"/media/press-releases/2016/hansa-medical-interim-report-july--september-2016/"},{"d":"2016-11-09","n":"Hansa Medical's Nomination Committee for the AGM 2017 appointed","u":"/media/press-releases/2016/hansa-medicals-nomination-committee-for-the-agm-2017-appointed/"},{"d":"2016-10-20","n":"Hansa Medical proposes a directed share issue","u":"/media/press-releases/2016/hansa-medical-proposes-a-directed-share-issue/"},{"d":"2016-10-20","n":"Notice of Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2016/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2016-10-11","n":"First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)","u":"/media/press-releases/2016/first-patient-treated-with-ides-in-phase-ii-study-in-acquired-thrombotic-thrombocytopenic-purpura-ttp/"},{"d":"2016-10-03","n":"First patient treated in Hansa Medical’s Highdes-study","u":"/media/press-releases/2016/first-patient-treated-in-hansa-medicals-highdes-study/"},{"d":"2016-08-23","n":"Top line results from the Swedish ongoing Phase II study with IdeS in sensitized patients presented","u":"/media/press-releases/2016/top-line-results-from-the-swedish-ongoing-phase-ii-study-with-ides-in-sensitized-patients-presented/"},{"d":"2016-07-21","n":"Hansa Medical Interim report April – June 2016","u":"/media/press-releases/2016/hansa-medical-interim-report-april--june-2016/"},{"d":"2016-07-19","n":"Hansa Medical acquires rights to cancer immunotherapy using antibody-modulating enzymes","u":"/media/press-releases/2016/hansa-medical-acquires-rights-to-cancer-immunotherapy-using-antibody-modulating-enzymes/"},{"d":"2016-07-19","n":"Hansa Medical initiates pivotal multicenter study in the US with IdeS for treatment of refractory highly sensitized kidney patients","u":"/media/press-releases/2016/hansa-medical-initiates-pivotal-multicenter-study-in-the-us-with-ides-for-treatment-of-refractory-highly-sensitized-kidney-patients/"},{"d":"2016-06-30","n":"Genovis AB enters settlement and license agreement with Promega Corporation in patent infringement case","u":"/media/press-releases/2016/genovis-ab-enters-settlement-and-license-agreement-with-promega-corporation-in-patent-infringement-case/"},{"d":"2016-06-15","n":"Successful desensitization with IdeS in all recruited patients in ongoing US Phase II study","u":"/media/press-releases/2016/successful-desensitization-with-ides-in-all-recruited-patients-in-ongoing-us-phase-ii-study/"},{"d":"2016-05-31","n":"Initial results from the ongoing Swedish Phase II study with IdeS in sensitized kidney transplant patients will be presented at TTS 2016","u":"/media/press-releases/2016/initial-results-from-the-ongoing-swedish-phase-ii-study-with-ides-in-sensitized-kidney-transplant-patients-will-be-presented-at-tts-2016/"},{"d":"2016-05-17","n":"Ongoing US study shows that IdeS allows for transplantation of highly sensitized patients","u":"/media/press-releases/2016/ongoing-us-study-shows-that-ides-allows-for-transplantation-of-highly-sensitized-patients/"},{"d":"2016-05-12","n":"Hansa Medical appoints Henk Doude van Troostwijk as Vice President, Commercial Operations","u":"/media/press-releases/2016/hansa-medical-appoints-henk-doude-van-troostwijk-as-vice-president-commercial-operations/"},{"d":"2016-05-12","n":"Resolutions adopted at the annual general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2016/resolutions-adopted-at-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2016-04-27","n":"Hansa Medical interim report January – March 2016","u":"/media/press-releases/2016/hansa-medical-interim-report-january--march-2016/"},{"d":"2016-04-19","n":"Patient recruitment completed in Phase II clinical study with IdeS in kidney transplantation","u":"/media/press-releases/2016/patient-recruitment-completed-in-phase-ii-clinical-study-with-ides-in-kidney-transplantation/"},{"d":"2016-04-12","n":"Notice of Annual General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2016/notice-of-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2016-04-06","n":"Proposed chairman Ulf Wiinberg buys shares in Hansa Medical","u":"/media/press-releases/2016/proposed-chairman-ulf-wiinberg-buys-shares-in-hansa-medical/"},{"d":"2016-04-04","n":"Ulf Wiinberg proposed as new chairman and Angelica Loskog new board member","u":"/media/press-releases/2016/ulf-wiinberg-proposed-as-new-chairman-and-angelica-loskog-new-board-member/"},{"d":"2016-04-04","n":"FDA clears Hansa Medical’s IND application for IdeS in kidney transplantation","u":"/media/press-releases/2016/fda-clears-hansa-medicals-ind-application-for-ides-in-kidney-transplantation/"},{"d":"2016-03-31","n":"Hansa Medical publishes the Annual Report for 2015","u":"/media/press-releases/2016/hansa-medical-publishes-the-annual-report-for-2015/"},{"d":"2016-03-24","n":"Hansa Medical postpones Annual General Meeting","u":"/media/press-releases/2016/hansa-medical-postpones-annual-general-meeting/"},{"d":"2016-03-11","n":"Study results presented in New England Journal of Medicine strengthen Hansa Medical's belief in the potential of IdeS","u":"/media/press-releases/2016/study-results-presented-in-new-england-journal-of-medicine-strengthen-hansa-medicals-belief-in-the-potential-of-ides/"},{"d":"2016-03-08","n":"Farstorps Gård AB has divested Hansa Medical shares","u":"/media/press-releases/2016/farstorps-gard-ab-has-divested-hansa-medical-shares/"},{"d":"2016-02-18","n":"Hansa Medical AB (publ) - Year-End Report 2015","u":"/media/press-releases/2016/hansa-medical-ab-publ---year-end-report-2015/"},{"d":"2015-12-08","n":"Swedish and international investors acquire 2 million shares in Hansa Medical AB from Farstorps Gård AB","u":"/media/press-releases/2015/swedish-and-international-investors-acquire-2-million-shares-in-hansa-medical-ab-from-farstorps-gard-ab/"},{"d":"2015-11-13","n":"Well attended Capital Markets Day by Hansa Medical","u":"/media/press-releases/2015/well-attended-capital-markets-day-by-hansa-medical/"},{"d":"2015-11-13","n":"Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies","u":"/media/press-releases/2015/data-shows-that-one-dose-of-ides-has-favorable-effect-and-completely-removes-hla-antibodies/"},{"d":"2015-11-10","n":"Data showing that IdeS can silence memory B-cells published in Journal of Immunology","u":"/media/press-releases/2015/data-showing-that-ides-can-silence-memory-b-cells-published-in-journal-of-immunology/"},{"d":"2015-11-02","n":"Trading of Hansa Medical's share initiated on Nasdaq Stockholm main market","u":"/media/press-releases/2015/trading-of-hansa-medicals-share-initiated-on-nasdaq-stockholm-main-market/"},{"d":"2015-10-28","n":"Hansa Medical interim report January – September 2015","u":"/media/press-releases/2015/hansa-medical-interim-report-january--september-2015/"},{"d":"2015-10-27","n":"Hansa Medical’s Nomination Committee appointed","u":"/media/press-releases/2015/hansa-medicals-nomination-committee-appointed/"},{"d":"2015-10-27","n":"Hansa Medical announces prospectus","u":"/media/press-releases/2015/hansa-medical-announces-prospectus/"},{"d":"2015-10-22","n":"Hansa Medical’s shares admitted to trading on Nasdaq Stockholm","u":"/media/press-releases/2015/hansa-medicals-shares-admitted-to-trading-on-nasdaq-stockholm/"},{"d":"2015-10-13","n":"Hansa Medical applies for stock exchange listing","u":"/media/press-releases/2015/hansa-medical-applies-for-stock-exchange-listing/"},{"d":"2015-10-06","n":"Hansa Medical invites to a Capital Markets Day in Stockholm, November the 13th 2015","u":"/media/press-releases/2015/hansa-medical-invites-to-a-capital-markets-day-in-stockholm-november-the-13th-2015/"},{"d":"2015-09-15","n":"Data from Hansa Medical’s First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015","u":"/media/press-releases/2015/data-from-hansa-medicals-first-phase-ii-study-of-ides-in-sensitized-kidney-transplantation-patients-presented-in-oral-session-at-esot-2015/"},{"d":"2015-09-14","n":"Hansa Medical receives FDA Orphan Drug Designation for IdeS","u":"/media/press-releases/2015/hansa-medical-receives-fda-orphan-drug-designation-for-ides/"},{"d":"2015-08-27","n":"Results from a clinical multicenter trial with HBP-assay published in Critical Care Medicine","u":"/media/press-releases/2015/results-from-a-clinical-multicenter-trial-with-hbp-assay-published-in-critical-care-medicine/"},{"d":"2015-08-25","n":"Hansa Medical Interim report January – June 2015","u":"/media/press-releases/2015/hansa-medical-interim-report-january--june-2015/"},{"d":"2015-08-11","n":"First patient in IdeS study at Cedars-Sinai Medical Center in Los Angeles receives kidney transplantation","u":"/media/press-releases/2015/first-patient-in-ides-study-at-cedars-sinai-medical-center-in-los-angeles-receives-kidney-transplantation/"},{"d":"2015-07-16","n":"Positive IdeS phase I data published in scientific journal PLOS ONE","u":"/media/press-releases/2015/positive-ides-phase-i-data-published-in-scientific-journal-plos-one/"},{"d":"2015-06-15","n":"First patient in IdeS phase II study transplanted","u":"/media/press-releases/2015/first-patient-in-ides-phase-ii-study-transplanted/"},{"d":"2015-06-10","n":"Board members, management and employees acquire Hansa Medical shares and warrants","u":"/media/press-releases/2015/board-members-management-and-employees-acquire-hansa-medical-shares-and-warrants/"},{"d":"2015-06-03","n":"Hans Schikan elected as new Board member in Hansa Medical AB (publ)","u":"/media/press-releases/2015/hans-schikan-elected-as-new-board-member-in-hansa-medical-ab-publ/"},{"d":"2015-06-03","n":"Resolutions adopted at the annual general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2015/resolutions-adopted-at-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2015-05-06","n":"Hansa Medical AB establishes a US medical advisory board for IdeS in kidney transplantation","u":"/media/press-releases/2015/hansa-medical-ab-establishes-a-us-medical-advisory-board-for-ides-in-kidney-transplantation/"},{"d":"2015-05-04","n":"Notice of Annual General Meeting of Hansa Medical; Hans Schikan nominated to the Board of Directors","u":"/media/press-releases/2015/notice-of-annual-general-meeting-of-hansa-medical-hans-schikan-nominated-to-the-board-of-directors/"},{"d":"2015-04-30","n":"Professor Stanley Jordan, a leading expert in transplant immunology, initiates IdeS-study in USA","u":"/media/press-releases/2015/professor-stanley-jordan-a-leading-expert-in-transplant-immunology-initiates-ides-study-in-usa/"},{"d":"2015-04-30","n":"Göran Arvidson new President and CEO of Hansa Medical","u":"/media/press-releases/2015/goran-arvidson-new-president-and-ceo-of-hansa-medical/"},{"d":"2015-04-29","n":"Hansa Medical publishes the Annual Report for 2014","u":"/media/press-releases/2015/hansa-medical-publishes-the-annual-report-for-2014/"},{"d":"2015-04-16","n":"Hansa Medical Interim report January – March 2015","u":"/media/press-releases/2015/hansa-medical-interim-report-january--march-2015/"},{"d":"2015-04-09","n":"Hansa Medical’s SEK 246 million rights issue fully subscribed","u":"/media/press-releases/2015/hansa-medicals-sek-246-million-rights-issue-fully-subscribed/"},{"d":"2015-03-20","n":"Hansa Medical postpones the publishing of the annual report for the financial year of 2014","u":"/media/press-releases/2015/hansa-medical-postpones-the-publishing-of-the-annual-report-for-the-financial-year-of-2014/"},{"d":"2015-03-18","n":"Hansa Medical announces prospectus","u":"/media/press-releases/2015/hansa-medical-announces-prospectus-2015-03-18/"},{"d":"2015-03-16","n":"Hansa Medical postpones annual general meeting","u":"/media/press-releases/2015/hansa-medical-postpones-annual-general-meeting/"},{"d":"2015-03-02","n":"Hansa Medical’s CFO appointed acting CEO","u":"/media/press-releases/2015/hansa-medicals-cfo-appointed-acting-ceo/"},{"d":"2015-02-23","n":"Change of ownership in Hansa Medical","u":"/media/press-releases/2015/change-of-ownership-in-hansa-medical/"},{"d":"2015-02-23","n":"Hansa Medical announces fully underwritten SEK 246 million rights issue","u":"/media/press-releases/2015/hansa-medical-announces-fully-underwritten-sek-246-million-rights-issue/"},{"d":"2015-02-19","n":"Hansa Medical appoints members of committees – Lars Björck and Hans Wigzell external members of scientific committee","u":"/media/press-releases/2015/hansa-medical-appoints-members-of-committees--lars-bjorck-and-hans-wigzell-external-members-of-scientific-committee/"},{"d":"2015-02-18","n":"Hansa Medical licensee Axis-Shield Diagnostic Limited enters agreement with Hangzhou Joinstar Biomedical Technology Co Ltd","u":"/media/press-releases/2015/hansa-medical-licensee-axis-shield-diagnostic-limited-enters-agreement-with-hangzhou-joinstar-biomedical-technology-co-ltd/"},{"d":"2015-02-18","n":"Comments to CEO presentation at Redeye on 17 February 2015 at 18.30","u":"/media/press-releases/2015/comments-to-ceo-presentation-at-redeye-on-17-february-2015-at-1830/"},{"d":"2015-02-16","n":"Hansa Medical AB has engaged Carnegie Investment Bank AB as financial advisor","u":"/media/press-releases/2015/hansa-medical-ab-has-engaged-carnegie-investment-bank-ab-as-financial-advisor/"},{"d":"2015-02-13","n":"Hansa Medical Year-End Report 2014","u":"/media/press-releases/2015/hansa-medical-year-end-report-2014/"},{"d":"2015-02-12","n":"Hansa Medical AB applies for listing on Nasdaq Stockholm","u":"/media/press-releases/2015/hansa-medical-ab-applies-for-listing-on-nasdaq-stockholm/"},{"d":"2015-02-12","n":"Hansa Medical develops second-generation IdeS molecules for repeat dosing","u":"/media/press-releases/2015/hansa-medical-develops-second-generation-ides-molecules-for-repeat-dosing/"},{"d":"2015-02-05","n":"Hansa Medical AB announces cooperation with Cedars-Sinai Medical Center’s Comprehensive Transplant Center and US transplantation expert Stanley Jordan","u":"/media/press-releases/2015/hansa-medical-ab-announces-cooperation-with-cedars-sinai-medical-centers-comprehensive-transplant-center-and-us-transplantation-expert-stanley-jordan/"},{"d":"2015-02-03","n":"Hansa Medical nomination committee for the Annual General Meeting 2015 has been established","u":"/media/press-releases/2015/hansa-medical-nomination-committee-for-the-annual-general-meeting-2015-has-been-established/"},{"d":"2015-02-02","n":"Hansa Medical AB takes up a 20 MSEK loan from principal shareholder Nexttobe AB","u":"/media/press-releases/2015/hansa-medical-ab-takes-up-a-20-msek-loan-from-principal-shareholder-nexttobe-ab/"},{"d":"2015-01-29","n":"Hansa Medical AB announces the formation of a medical advisory board for IdeS in anti-GBM disease","u":"/media/press-releases/2015/hansa-medical-ab-announces-the-formation-of-a-medical-advisory-board-for-ides-in-anti-gbm-disease/"},{"d":"2015-01-27","n":"Hansa Medical appoints Göran Arvidson as CFO","u":"/media/press-releases/2015/hansa-medical-appoints-goran-arvidson-as-cfo/"},{"d":"2015-01-20","n":"Successful Phase 2 Study of IdeS in Highly Sensitized Dialysis Patients awaiting Kidney Transplantation","u":"/media/press-releases/2015/successful-phase-2-study-of-ides-in-highly-sensitized-dialysis-patients-awaiting-kidney-transplantation/"},{"d":"2015-01-15","n":"Hansa Medical financial reporting dates","u":"/media/press-releases/2015/hansa-medical-financial-reporting-dates/"},{"d":"2015-01-07","n":"Last patient included in IdeS clinical Phase II study","u":"/media/press-releases/2015/last-patient-included-in-ides-clinical-phase-ii-study/"},{"d":"2014-11-25","n":"Fredrik Lindgren appointed new President and CEO of Hansa Medical","u":"/media/press-releases/2014/fredrik-lindgren-appointed-new-president-and-ceo-of-hansa-medical/"},{"d":"2014-11-11","n":"Genovis AB files complaint for patent infringement by Promega Inc.","u":"/media/press-releases/2014/genovis-ab-files-complaint-for-patent-infringement-by-promega-inc/"},{"d":"2014-10-01","n":"Birgit Stattin Norinder appointed new chairman of Hansa Medical’s board of directors","u":"/media/press-releases/2014/birgit-stattin-norinder-appointed-new-chairman-of-hansa-medicals-board-of-directors/"},{"d":"2014-09-29","n":"Bo Håkansson has passed away","u":"/media/press-releases/2014/bo-hakansson-has-passed-away/"},{"d":"2014-08-18","n":"The Hansa Medical candidate drug IdeS has enabled successful kidney transplantation","u":"/media/press-releases/2014/the-hansa-medical-candidate-drug-ides-has-enabled-successful-kidney-transplantation/"},{"d":"2014-07-25","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2014","u":"/media/press-releases/2014/hansa-medical-ab-publ---interim-report-january-1---june-30-2014/"},{"d":"2014-07-09","n":"Phase II IdeS-study initiated in Uppsala","u":"/media/press-releases/2014/phase-ii-ides-study-initiated-in-uppsala/"},{"d":"2014-07-01","n":"Hansa Medical to present IdeS at the 2014 World Transplant Congress in San Francisco, July 27","u":"/media/press-releases/2014/hansa-medical-to-present-ides-at-the-2014-world-transplant-congress-in-san-francisco-july-27/"},{"d":"2014-06-11","n":"Hansa Medical to present IdeS at the 2014 BIO International Convention in San Diego, USA, on June 26","u":"/media/press-releases/2014/hansa-medical-to-present-ides-at-the-2014-bio-international-convention-in-san-diego-usa-on-june-26/"},{"d":"2014-05-06","n":"Swedish Medical Products Agency approves Hansa Medical’s clinical Phase II-study application with IdeS","u":"/media/press-releases/2014/swedish-medical-products-agency-approves-hansa-medicals-clinical-phase-ii-study-application-with-ides/"},{"d":"2014-05-02","n":"Notice of Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2014/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2014-04-30","n":"Hansa Medical’s Annual Report of 2013 has been published (In Swedish)","u":"/media/press-releases/2014/hansa-medicals-annual-report-of-2013-has-been-published-in-swedish/"},{"d":"2014-04-11","n":"Hansa Medical’s rights issue oversubscribed","u":"/media/press-releases/2014/hansa-medicals-rights-issue-oversubscribed/"},{"d":"2014-04-10","n":"Hansa Medical to present IdeS at the World Orphan Drug Congress USA, April 24 in Washington D.C.","u":"/media/press-releases/2014/hansa-medical-to-present-ides-at-the-world-orphan-drug-congress-usa-april-24-in-washington-dc/"},{"d":"2014-04-10","n":"Hansa Medical appoints Medical Advisory Board","u":"/media/press-releases/2014/hansa-medical-appoints-medical-advisory-board/"},{"d":"2014-04-03","n":"The 2014 Annual General Meeting of Hansa Medical has been rescheduled to June 3","u":"/media/press-releases/2014/the-2014-annual-general-meeting-of-hansa-medical-has-been-rescheduled-to-june-3/"},{"d":"2014-03-19","n":"Hansa Medical publishes prospectus regerading preferential rights issue at SEK 37 million","u":"/media/press-releases/2014/hansa-medical-publishes-prospectus-regerading-preferential-rights-issue-at-sek-37-million/"},{"d":"2014-03-05","n":"Bulletin from the extraordinary general meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2014/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2014-03-03","n":"Hansa Medical files application for phase II-study with IdeS","u":"/media/press-releases/2014/hansa-medical-files-application-for-phase-ii-study-with-ides/"},{"d":"2014-02-14","n":"Notice of extraordinary meeting of shareholders in Hansa Medical AB (publ)","u":"/media/press-releases/2014/notice-of-extraordinary-meeting-of-shareholders-in-hansa-medical-ab-publ/"},{"d":"2014-02-14","n":"Funding of the Phase II study with IdeS secured","u":"/media/press-releases/2014/funding-of-the-phase-ii-study-with-ides-secured/"},{"d":"2014-02-05","n":"Year-end report 2013","u":"/media/press-releases/2014/year-end-report-2013/"},{"d":"2014-01-27","n":"Succesfully completed Phase I study with IdeS","u":"/media/press-releases/2014/succesfully-completed-phase-i-study-with-ides/"},{"d":"2013-11-18","n":"Hansa Medical receives SEK 3.4 million grant from VINNOVA to carry out Phase II study with IdeS","u":"/media/press-releases/2013/hansa-medical-receives-sek-34-million-grant-from-vinnova-to-carry-out-phase-ii-study-with-ides/"},{"d":"2013-11-06","n":"U.S Department of Health and Human Services  reports critical need for better prediction of severe sepsis.","u":"/media/press-releases/2013/us-department-of-health-and-human-services--reports-critical-need-for-better-prediction-of-severe-sepsis/"},{"d":"2013-11-05","n":"Hansa Medical and Axis-Shield report most promising results from pivotal clinical trial with HBP-analysis","u":"/media/press-releases/2013/hansa-medical-and-axis-shield-report-most-promising-results-from-pivotal-clinical-trial-with-hbp-analysis/"},{"d":"2013-11-04","n":"All healthy subjects have been treated in Hansa Medicals´ Phase I-study with IdeS","u":"/media/press-releases/2013/all-healthy-subjects-have-been-treated-in-hansa-medicals-phase-i-study-with-ides/"},{"d":"2013-10-03","n":"Hansa Medical strengthens its liquidity","u":"/media/press-releases/2013/hansa-medical-strengthens-its-liquidity/"},{"d":"2013-07-25","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2013","u":"/media/press-releases/2013/hansa-medical-ab-publ---interim-report-january-1---june-30-2013/"},{"d":"2013-05-15","n":"Promising research results with EndoS published in PNAS","u":"/media/press-releases/2013/promising-research-results-with-endos-published-in-pnas/"},{"d":"2013-05-07","n":"Bulletin from the Annual General Meeting of Hansa Medical AB (publ) 2013","u":"/media/press-releases/2013/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2013/"},{"d":"2013-04-15","n":"Hansa Medical’s annual report of 2012 (in Swedish) has been published","u":"/media/press-releases/2013/hansa-medicals-annual-report-of-2012-in-swedish-has-been-published/"},{"d":"2013-03-28","n":"Notice of Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2013/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2013-03-22","n":"Hansa Medical enters liquidity provider agreement with Erik Penser Bankaktiebolag","u":"/media/press-releases/2013/hansa-medical-enters-liquidity-provider-agreement-with-erik-penser-bankaktiebolag/"},{"d":"2013-03-21","n":"The Annual General Meeting of Hansa Medical has been rescheduled to May 6, 2013","u":"/media/press-releases/2013/the-annual-general-meeting-of-hansa-medical-has-been-rescheduled-to-may-6-2013/"},{"d":"2013-03-18","n":"Hansa Medical’s clinical Phase I study with IdeS has been initiated","u":"/media/press-releases/2013/hansa-medicals-clinical-phase-i-study-with-ides-has-been-initiated/"},{"d":"2013-02-07","n":"Year-end report 2012","u":"/media/press-releases/2013/year-end-report-2012/"},{"d":"2013-02-06","n":"Hansa Medical receive approval from Swedish Medical Products Agency to begin clinical Phase I study with IdeS","u":"/media/press-releases/2013/hansa-medical-receive-approval-from-swedish-medical-products-agency-to-begin-clinical-phase-i-study-with-ides/"},{"d":"2012-12-18","n":"Hansa Medical development partner Axis-Shield Diagnostics launches CE-marked ELISA assay for measurement of HBP","u":"/media/press-releases/2012/hansa-medical-development-partner-axis-shield-diagnostics-launches-ce-marked-elisa-assay-for-measurement-of-hbp/"},{"d":"2012-11-14","n":"HBP-assay website launched","u":"/media/press-releases/2012/hbp-assay-website-launched/"},{"d":"2012-07-26","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2012","u":"/media/press-releases/2012/hansa-medical-ab-publ---interim-report-january-1---june-30-2012/"},{"d":"2012-05-15","n":"Bulletin from the Annual General Meeting of Hansa Medical AB (publ) 2012","u":"/media/press-releases/2012/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2012/"},{"d":"2012-04-23","n":"Hansa Medical’s annual report of 2011 (in Swedish) has been published","u":"/media/press-releases/2012/hansa-medicals-annual-report-of-2011-in-swedish-has-been-published/"},{"d":"2012-03-22","n":"Hansa Medical’s rights issue with preferential rights has been completed","u":"/media/press-releases/2012/hansa-medicals-rights-issue-with-preferential-rights-has-been-completed/"},{"d":"2012-03-20","n":"HMD-301 for diagnosis of Urinary Tract Infection: novel clinical results published","u":"/media/press-releases/2012/hmd-301-for-diagnosis-of-urinary-tract-infection-novel-clinical-results-published/"},{"d":"2012-03-14","n":"Hansa Medical granted patents in the United States and Europe for the medical use of IdeS","u":"/media/press-releases/2012/hansa-medical-granted-patents-in-the-united-states-and-europe-for-the-medical-use-of-ides/"},{"d":"2012-03-08","n":"Hansa Medical has been granted European patent for diagnostic method HMD-301","u":"/media/press-releases/2012/hansa-medical-has-been-granted-european-patent-for-diagnostic-method-hmd-301/"},{"d":"2012-02-15","n":"Annual General Meeting of Hansa Medical rescheduled to May 14, 2012","u":"/media/press-releases/2012/annual-general-meeting-of-hansa-medical-rescheduled-to-may-14-2012/"},{"d":"2012-02-09","n":"Year-End Release 2011","u":"/media/press-releases/2012/year-end-release-2011/"},{"d":"2012-01-25","n":"Directed new share issue by Hansa Medical AB (publ) completed","u":"/media/press-releases/2012/directed-new-share-issue-by-hansa-medical-ab-publ-completed/"},{"d":"2012-01-10","n":"Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2012/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2011-12-14","n":"Notice of extraordinary meeting of shareholders in Hansa Medical AB (publ)","u":"/media/press-releases/2011/notice-of-extraordinary-meeting-of-shareholders-in-hansa-medical-ab-publ/"},{"d":"2011-12-08","n":"Hansa Medical executes a directed new share issue to NXT2B immediately followed by a guaranteed preferential rights issue – In total MSEK 46 is raised","u":"/media/press-releases/2011/hansa-medical-executes-a-directed-new-share-issue-to-nxt2b-immediately-followed-by-a-guaranteed-preferential-rights-issue--in-total-msek-46-is-raised/"},{"d":"2011-12-08","n":"Hansa Medical closes preclinical research project and focuses on clinical development of enzyme based treatment of rare diseases","u":"/media/press-releases/2011/hansa-medical-closes-preclinical-research-project-and-focuses-on-clinical-development-of-enzyme-based-treatment-of-rare-diseases/"},{"d":"2011-07-28","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2011","u":"/media/press-releases/2011/hansa-medical-ab-publ---interim-report-january-1---june-30-2011/"},{"d":"2011-06-23","n":"Bo Håkansson increases ownership in Hansa Medical AB (publ) through acquisition of more than 1 million shares","u":"/media/press-releases/2011/bo-hakansson-increases-ownership-in-hansa-medical-ab-publ-through-acquisition-of-more-than-1-million-shares/"},{"d":"2011-06-17","n":"Hansa Medical’s rights issue amounting SEK 29 million has been oversubscribed","u":"/media/press-releases/2011/hansa-medicals-rights-issue-amounting-sek-29-million-has-been-oversubscribed/"},{"d":"2011-06-01","n":"Hansa Medical arranges information meetings in Malmö and Stockholm","u":"/media/press-releases/2011/hansa-medical-arranges-information-meetings-in-malmo-and-stockholm/"},{"d":"2011-05-23","n":"Hansa Medical publishes financial information from its prospectus regarding the new share issue","u":"/media/press-releases/2011/hansa-medical-publishes-financial-information-from-its-prospectus-regarding-the-new-share-issue/"},{"d":"2011-05-23","n":"Hansa Medical’s prospectus for the new share issue of MSEK 29 has been published","u":"/media/press-releases/2011/hansa-medicals-prospectus-for-the-new-share-issue-of-msek-29-has-been-published/"},{"d":"2011-05-23","n":"Hansa Medical establish agreement on subscription commitment and issuing guarantee","u":"/media/press-releases/2011/hansa-medical-establish-agreement-on-subscription-commitment-and-issuing-guarantee/"},{"d":"2011-05-13","n":"Bulletin from the Annual General Meeting of Hansa Medical AB (publ) 2011","u":"/media/press-releases/2011/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2011/"},{"d":"2011-05-11","n":"HMD-301 for diagnosis of bacterial meningitis: novel clinical results published","u":"/media/press-releases/2011/hmd-301-for-diagnosis-of-bacterial-meningitis-novel-clinical-results-published/"},{"d":"2011-04-28","n":"Hansa Medical’s annual report of 2010 (In Swedish) now available at corporate website","u":"/media/press-releases/2011/hansa-medicals-annual-report-of-2010-in-swedish-now-available-at-corporate-website/"},{"d":"2011-04-11","n":"Notice of Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2011/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2011-04-11","n":"Hansa Medicals’ Board of Directors recommend AGM to issue new shares to raise SEK 29 million","u":"/media/press-releases/2011/hansa-medicals-board-of-directors-recommend-agm-to-issue-new-shares-to-raise-sek-29-million/"},{"d":"2011-04-01","n":"Annual General Meeting of Hansa Medical rescheduled to May 12, 2011","u":"/media/press-releases/2011/annual-general-meeting-of-hansa-medical-rescheduled-to-may-12-2011/"},{"d":"2011-03-23","n":"Hansa Medical terminates liquidity provider agreement","u":"/media/press-releases/2011/hansa-medical-terminates-liquidity-provider-agreement/"},{"d":"2011-03-21","n":"Hansa Medical and Axis-Shield begin multi-centre clinical study of HBP assay for diagnosis of severe sepsis","u":"/media/press-releases/2011/hansa-medical-and-axis-shield-begin-multi-centre-clinical-study-of-hbp-assay-for-diagnosis-of-severe-sepsis/"},{"d":"2011-02-10","n":"Year-End Release 2010","u":"/media/press-releases/2011/year-end-release-2010/"},{"d":"2011-01-10","n":"Hansa Medicals' development partner Axis-Shield signs option agreement with Bio-Rad Laboratories for commercialisation of Heparin Binding Protein","u":"/media/press-releases/2011/hansa-medicals-development-partner-axis-shield-signs-option-agreement-with-bio-rad-laboratories-for-commercialisation-of-heparin-binding-protein/"},{"d":"2010-09-20","n":"Hansa Medical AB receives milestone payment for achieving a strong alpha-11 patent portfolio","u":"/media/press-releases/2010/hansa-medical-ab-receives-milestone-payment-for-achieving-a-strong-alpha-11-patent-portfolio/"},{"d":"2010-09-06","n":"Hansa Medical AB enters license agreement with Human Genome Sciences Inc.","u":"/media/press-releases/2010/hansa-medical-ab-enters-license-agreement-with-human-genome-sciences-inc/"},{"d":"2010-07-29","n":"Hansa Medical AB (publ) - Interim report January 1 - June 30 2010","u":"/media/press-releases/2010/hansa-medical-ab-publ---interim-report-january-1---june-30-2010/"},{"d":"2010-04-30","n":"Bulletin from the Annual General Meeting of Hansa Medical AB (publ) 2010","u":"/media/press-releases/2010/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2010/"},{"d":"2010-04-20","n":"Final outcome of Hansa Medical’s rights issue","u":"/media/press-releases/2010/final-outcome-of-hansa-medicals-rights-issue/"},{"d":"2010-04-16","n":"Hansa Medical’s rights issue oversubscribed","u":"/media/press-releases/2010/hansa-medicals-rights-issue-oversubscribed/"},{"d":"2010-04-15","n":"Hansa Medical’s Annual Report 2009 (In Swedish) now available online","u":"/media/press-releases/2010/hansa-medicals-annual-report-2009-in-swedish-now-available-online/"},{"d":"2010-04-15","n":"Hansa Medical’s Annual Report 2009 (In Swedish) now available online","u":"/media/press-releases/2010/hansa-medicals-annual-report-2009-in-swedish-now-available-online-2010-04-15/"},{"d":"2010-03-26","n":"Notice of Annual General Meeting in Hansa Medical AB (publ)","u":"/media/press-releases/2010/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/"},{"d":"2010-03-19","n":"Hansa Medical rights issue prospectus in Swedish has been published","u":"/media/press-releases/2010/hansa-medical-rights-issue-prospectus-in-swedish-has-been-published/"},{"d":"2010-03-04","n":"Hansa Medical to implement guaranteed rights issue amounting to SEK 27 million","u":"/media/press-releases/2010/hansa-medical-to-implement-guaranteed-rights-issue-amounting-to-sek-27-million/"},{"d":"2010-02-10","n":"Year-End Release 2009","u":"/media/press-releases/2010/year-end-release-2009/"},{"d":"2009-09-28","n":"Clinical research results with HMD-301 published in Clinical Infectious Diseases","u":"/media/press-releases/2009/clinical-research-results-with-hmd-301-published-in-clinical-infectious-diseases/"},{"d":"2009-07-30","n":"Interim report January 1 – June 30, 2009","u":"/media/press-releases/2009/interim-report-january-1--june-30-2009/"},{"d":"2009-06-22","n":"Hansa Medical and Inverness Medical Innovations launch partnership agreement for the development of biopharmaceuticals to treat rheumatoid arthritis","u":"/media/press-releases/2009/hansa-medical-and-inverness-medical-innovations-launch-partnership-agreement-for-the-development-of-biopharmaceuticals-to-treat-rheumatoid-arthritis/"},{"d":"2009-06-15","n":"Hansa Medical and Axis-Shield enter development and license agreement regarding novel biomarker for severe sepsis","u":"/media/press-releases/2009/hansa-medical-and-axis-shield-enter-development-and-license-agreement-regarding-novel-biomarker-for-severe-sepsis/"},{"d":"2009-05-07","n":"Hansa Medical receives financing from VINNOVA for research project","u":"/media/press-releases/2009/hansa-medical-receives-financing-from-vinnova-for-research-project/"},{"d":"2009-04-30","n":"Press release from the 2009 Annual General Meeting of Hansa Medical AB","u":"/media/press-releases/2009/press-release-from-the-2009-annual-general-meeting-of-hansa-medical-ab/"},{"d":"2009-04-15","n":"Hansa Medical’s Election Committee moves for re-election of the Board","u":"/media/press-releases/2009/hansa-medicals-election-committee-moves-for-re-election-of-the-board/"},{"d":"2009-04-05","n":"Annual Report 2008 (In Swedish)","u":"/media/press-releases/2009/annual-report-2008-in-swedish/"},{"d":"2009-04-03","n":"Hansa Medical divests research project","u":"/media/press-releases/2009/hansa-medical-divests-research-project/"},{"d":"2009-03-31","n":"Notice of the Annual General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2009/notice-of-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2009-02-10","n":"Year-End Release 2008","u":"/media/press-releases/2009/year-end-release-2008/"},{"d":"2008-11-24","n":"Hansa Medical changes certified adviser","u":"/media/press-releases/2008/hansa-medical-changes-certified-adviser/"},{"d":"2008-08-21","n":"Interim report January 1 – June 30, 2008","u":"/media/press-releases/2008/interim-report-january-1--june-30-2008/"},{"d":"2008-05-15","n":"Hansa Medical redeems convertible loan – positive earnings effect of SEK 15.1 M","u":"/media/press-releases/2008/hansa-medical-redeems-convertible-loan--positive-earnings-effect-of-sek-151-m/"},{"d":"2008-05-08","n":"Press release from the Annual General Meeting of Hansa Medical AB (publ) on May 7, 2008","u":"/media/press-releases/2008/press-release-from-the-annual-general-meeting-of-hansa-medical-ab-publ-on-may-7-2008/"},{"d":"2008-04-23","n":"Annual Report 2007 (In Swedish)","u":"/media/press-releases/2008/annual-report-2007-in-swedish/"},{"d":"2008-04-08","n":"Notice of the Annual General Meeting of Hansa Medical AB (publ)","u":"/media/press-releases/2008/notice-of-the-annual-general-meeting-of-hansa-medical-ab-publ/"},{"d":"2008-02-28","n":"Year-End Release 2007","u":"/media/press-releases/2008/year-end-release-2007/"},{"d":"2008-01-15","n":"Hansa Medical acquires all assets in Cartela AB","u":"/media/press-releases/2008/hansa-medical-acquires-all-assets-in-cartela-ab/"},{"d":"2007-11-20","n":"Chairman of the Board acquires shares","u":"/media/press-releases/2007/chairman-of-the-board-acquires-shares/"},{"d":"2007-10-17","n":"Hansa Medical listed on First North","u":"/media/press-releases/2007/hansa-medical-listed-on-first-north/"},{"d":"2007-10-12","n":"Hansa Medical approved for trading on First North","u":"/media/press-releases/2007/hansa-medical-approved-for-trading-on-first-north/"},{"d":"2007-10-03","n":"Hansa Medical’s new share issue totaling SEK 38 M fully subscribed","u":"/media/press-releases/2007/hansa-medicals-new-share-issue-totaling-sek-38-m-fully-subscribed/"}]

Quotes are delayed 15 minutes. Information provided by Cision.

Historical Stock Quote

Information provided by Cision.

Investment Calculator

Chart the performance of an investment in HNSA relative to market indices or to another stock over time.

Enter time period

Enter number of shares OR the value of your holdings

Information provided by Cision.

The Board of Hansa Medical AB (publ) has prepared this prospectus due to the listing.

Listing prospectus